Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

4 recruiting

Phase 1

5(83.3%)

Phase 3

1(16.7%)

6Total

Phase 1(5)

Phase 3(1)

Loading network data...

Showing 6 of 6 trials

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Role: collaborator

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

Role: lead

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

Role: collaborator

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Role: lead

A Study of IBI3032 in Healthy Participants

Role: lead

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

Role: collaborator

All 6 trials loaded